Gestational Trophoblastic Disease: Clinical Management and Outcomes: A Retrospective Study
Received: 16 Dec 2024 | Accepted: 04 Feb 2025 | Available online: 20 Feb 2025Vildan NALBANT GÜRERa , Mehmet KÜÇÜKBAŞa , Dilan ÜNSAL KAYAa , Fatma Canan KARABAŞa , Ateş KARATEKEa
aGöztepe Prof. Dr. Süleyman Yalçın City Hospital, Department of Obstetrics and Gynecology, İstanbul, Türkiye
JCOG.
DOI: 10.5336/jcog.2024-107610
Article Language: EN
Copyright Ⓒ 2025 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (
http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: Evaluation of clinical management, pathological features and outcomes of patients diagnosed with gestational trophoblastic disease (GTD) in our clinic. Material and Methods: 39 patients who were diagnosed with GTD in our clinic between October 2016 and June 2020 were included in this study. Demographic, clinical and pathological characteristics of the patients, treatment and follow-ups and outcomes were evaluated retrospectively. Results: In our study, a total of 39 GTD cases, including 35 cases reported as hydatiform mole (HM) (14 complete moles, 19 partial moles, 2 complete/partial moles cannot be differentiated) and 4 cases of gestational trophoblastic neoplasia (GTN) were included in the study. Post-molar GTN was diagnosed in 2 patients. Omentum biopsy was performed in a 41-year-old patient with a history of abdominal pain with elevated human chorionic gonadotropin levels and a history of total abdominal hysterectomy and bilateral salpingo-oophorectomy 8 months ago due to adnexal mass. Biopsy result revealed a malignant tumor with a trophoblastic reaction, the patient received 8 courses of Actinomycin-D treatment, and deceased due to diffuse metastatic disease. Conclusion: Our first-line treatment in GTD is D&C. In cases diagnosed with GTN, hysterectomy was preferred in advanced age patients and the patients who completed their fertility. It has been observed that this application reduces the need for and the duration of subsequent chemotherapy.